Literature DB >> 27160903

Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.

Pradeep Chaluvally-Raghavan1, Kang Jin Jeong2, Sunila Pradeep3, Andreia Machado Silva4, Shuangxing Yu2, Wenbin Liu5, Tyler Moss2, Cristian Rodriguez-Aguayo4, Dong Zhang2, Prahlad Ram2, Jinsong Liu6, Yiling Lu2, Gabriel Lopez-Berestein7, George A Calin7, Anil K Sood8, Gordon B Mills9.   

Abstract

3q26.2 amplification in high-grade serous ovarian cancer leads to increased expression of mature microRNA miR551b-3p, which is associated with poor clinical outcome. Importantly, miR551b-3p contributes to resistance to apoptosis and increased survival and proliferation of cancer cells in vitro and in vivo. miR551b-3p upregulates STAT3 protein levels, and STAT3 is required for the effects of miR551b-3p on cell proliferation. Rather than decreasing levels of target mRNA as expected, we demonstrate that miR551b-3p binds a complementary sequence on the STAT3 promoter, recruiting RNA polymerase II and the TWIST1 transcription factor to activate STAT3 transcription, and thus directly upregulates STAT3 expression. Furthermore, anti-miR551b reduced STAT3 expression in ovarian cancer cells in vitro and in vivo and reduced ovarian cancer growth in vivo. Together, our data demonstrate a role for miR551b-3p in transcriptional activation. Thus, miR551b-3p represents a promising candidate biomarker and therapeutic target in ovarian cancer.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27160903      PMCID: PMC4914391          DOI: 10.1016/j.celrep.2016.04.034

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  32 in total

1.  Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Authors:  Astrid M Eder; Xiaomei Sui; Daniel G Rosen; Laura K Nolden; Kwai Wa Cheng; John P Lahad; Madhuri Kango-Singh; Karen H Lu; Carla L Warneke; Edward N Atkinson; Isabelle Bedrosian; Khandan Keyomarsi; Wen-lin Kuo; Joe W Gray; Jerry C P Yin; Jinsong Liu; Georg Halder; Gordon B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

Review 2.  Small RNA and transcriptional upregulation.

Authors:  Victoria Portnoy; Vera Huang; Robert F Place; Long-Cheng Li
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-05-02       Impact factor: 9.957

Review 3.  Ovarian cancer stem cell markers: prognostic and therapeutic implications.

Authors:  Daniela Burgos-Ojeda; Bo R Rueda; Ronald J Buckanovich
Journal:  Cancer Lett       Date:  2012-02-11       Impact factor: 8.679

4.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Authors:  Charles N Landen; Arturo Chavez-Reyes; Corazon Bucana; Rosemarie Schmandt; Michael T Deavers; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

5.  PIK3CA is implicated as an oncogene in ovarian cancer.

Authors:  L Shayesteh; Y Lu; W L Kuo; R Baldocchi; T Godfrey; C Collins; D Pinkel; B Powell; G B Mills; J W Gray
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

6.  microPIR: an integrated database of microRNA target sites within human promoter sequences.

Authors:  Jittima Piriyapongsa; Chaiwat Bootchai; Chumpol Ngamphiw; Sissades Tongsima
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

7.  Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells.

Authors:  Vera Huang; Jiashun Zheng; Zhongxia Qi; Ji Wang; Robert F Place; Jingwei Yu; Hao Li; Long-Cheng Li
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

8.  Chromatin-associated RNA interference components contribute to transcriptional regulation in Drosophila.

Authors:  Filippo M Cernilogar; Maria Cristina Onorati; Greg O Kothe; A Maxwell Burroughs; Krishna Mohan Parsi; Achim Breiling; Federica Lo Sardo; Alka Saxena; Keita Miyoshi; Haruhiko Siomi; Mikiko C Siomi; Piero Carninci; David S Gilmour; Davide F V Corona; Valerio Orlando
Journal:  Nature       Date:  2011-11-06       Impact factor: 49.962

9.  Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs.

Authors:  Yijun Zhang; Miaomiao Fan; Xue Zhang; Feng Huang; Kang Wu; Junsong Zhang; Jun Liu; Zhuoqiong Huang; Haihua Luo; Liang Tao; Hui Zhang
Journal:  RNA       Date:  2014-10-21       Impact factor: 4.942

10.  Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.

Authors:  Lifeng Yang; Tyler Moss; Lingegowda S Mangala; Juan Marini; Hongyun Zhao; Stephen Wahlig; Guillermo Armaiz-Pena; Dahai Jiang; Abhinav Achreja; Julia Win; Rajesha Roopaimoole; Cristian Rodriguez-Aguayo; Imelda Mercado-Uribe; Gabriel Lopez-Berestein; Jinsong Liu; Takashi Tsukamoto; Anil K Sood; Prahlad T Ram; Deepak Nagrath
Journal:  Mol Syst Biol       Date:  2014-05-05       Impact factor: 11.429

View more
  37 in total

1.  Prostaglandin E2 triggers cytochrome P450 17α hydroxylase overexpression via signal transducer and activator of transcription 3 phosphorylation and promotes invasion in endometrial cancer.

Authors:  Jieqi Ke; Zhen Shen; Min Li; Cheng Peng; Ping Xu; Meimei Wang; Yi Zhu; Xuefen Zhang; Dabao Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

3.  miRNA activation is an endogenous gene expression pathway.

Authors:  Luis M Vaschetto
Journal:  RNA Biol       Date:  2018-04-03       Impact factor: 4.652

Review 4.  Proteomics advances for precision therapy in ovarian cancer.

Authors:  Marilyne Labrie; Nicholas D Kendsersky; Hongli Ma; Lydia Campbell; Jennifer Eng; Koei Chin; Gordon B Mills
Journal:  Expert Rev Proteomics       Date:  2019-09-13       Impact factor: 3.940

5.  MicroRNA-1251-5p Promotes Carcinogenesis and Autophagy via Targeting the Tumor Suppressor TBCC in Ovarian Cancer Cells.

Authors:  Yang Shao; Xiaomin Liu; Jiao Meng; Xiaofei Zhang; Zhongliang Ma; Gong Yang
Journal:  Mol Ther       Date:  2019-06-14       Impact factor: 11.454

6.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

Review 7.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

8.  Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.

Authors:  Deepak Parashar; Bindu Nair; Anjali Geethadevi; Jasmine George; Ajay Nair; Shirng-Wern Tsaih; Ishaque P Kadamberi; Gopa Kumar Gopinadhan Nair; Yiling Lu; Ramani Ramchandran; Denise S Uyar; Janet S Rader; Prahlad T Ram; Gordon B Mills; Sunila Pradeep; Pradeep Chaluvally-Raghavan
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 12.701

9.  STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Authors:  Uksha Saini; Adrian A Suarez; Shan Naidu; John J Wallbillich; Kristin Bixel; Ross A Wanner; Jason Bice; Raleigh D Kladney; Jenny Lester; Beth Y Karlan; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2018-01-16       Impact factor: 12.701

10.  Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.

Authors:  Anjali Geethadevi; Ajay Nair; Deepak Parashar; Zhiqiang Ku; Wei Xiong; Hui Deng; Yongsheng Li; Jasmine George; Donna M McAllister; Yunguang Sun; Ishaque P Kadamberi; Prachi Gupta; Michael B Dwinell; William H Bradley; Janet S Rader; Hallgeir Rui; Robert F Schwabe; Ningyan Zhang; Sunila Pradeep; Zhiqiang An; Pradeep Chaluvally-Raghavan
Journal:  Cancer Res       Date:  2021-08-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.